P2X3 Antagonist Stepwise Synthesis for Scalable Clinical Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing P2X3 antagonists are inefficient and lack a comprehensive process for large-scale production of clinically useful compounds.
Innovation Solution
A multi-step synthetic process involving various reagents and conditions is described to produce methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (Compound 1), including the use of amide coupling reagents, brominating agents, and hydrogenation catalysts, to achieve high-yield production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current synthesis methods are used, then P2X3 antagonists can be produced, but the synthesis efficiency is low and large-scale production is not feasible
Solution Approach 1:
The patent divides the synthesis of P2X3 antagonists into multiple discrete steps, each with optimized conditions. The multi-step process includes separate reactions for forming the imidazopyridine core, introducing fluorine atoms, adding the morpholine carboxylate group, and final purification. This segmentation allows each step to be independently optimized and scaled, transforming an inefficient single-step or unoptimized process into a scalable manufacturing protocol.
2Productivity
If high-yield production is achieved, then clinically useful quantities are produced, but the process complexity increases
Solution Approach 1:
The patent employs preliminary protection strategies where specific functional groups are protected before undergoing reactions that might interfere with them. For example, the morpholine nitrogen may be protected as a carbamate or carbonyl derivative before participating in coupling reactions, then deprotected in a final step. This preliminary action prevents side reactions and simplifies the overall process by eliminating the need for complex purification steps between reactions, thereby maintaining high yield while managing complexity.
Solution Approach 2:
The patent optimizes reaction parameters such as temperature, solvent selection, catalyst loading, and reaction time for each synthesis step to maximize yield. By systematically adjusting these parameters, the process achieves high-yield production without requiring excessively complex equipment or procedures. For instance, conducting reactions at elevated temperatures or using specific catalysts can dramatically improve yields while maintaining relatively simple process conditions.
3Quantity of substance
If a comprehensive synthesis process is developed, then clinically useful compounds are produced, but the manufacturing time increases
Solution Approach 1:
The patent designs the synthesis process to minimize idle time between steps. Reactions are sequenced so that the product of one step can be directly used in the next without isolation or extensive purification. The process maintains continuous useful action by having overlapping operation times for different reaction vessels, allowing multiple transformations to occur simultaneously in parallel. This continuity dramatically reduces total manufacturing time while producing clinically useful quantities of P2X3 antagonists.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables the efficient and scalable synthesis of P2X3 antagonists, facilitating their use in pharmaceutical applications.
Implementation Method 1
contacting a compound with the structure: with an amide coupling reagent and methylamine
Implementation Method 2
contacting a compound with the structure: with a brominating reagent
Implementation Method 3
contacting a compound with the structure: with hydrogen and a hydrogenation catalyst
Data Source
AI summary
Described herein are two processes for the preparation of methyl (5)-2-((2-(2,6-difLuoro-4-(methylcarbamol)phenyl)-7-methylimidaz[1,2-a]pyridine-3-yl)methyl)morpholine-4-carboxylate, a P2X3 antagonist, in a stepwise manner and chemical intermediates used in the synthetic processes.